Alpha Tau Medical Ltd. (NASDAQ:DRTS) Stock Has Consensus Target Price of $15.40

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report) have been assigned a consensus rating of “Hold” from the eight research firms that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $15.40.

Several research firms have issued reports on DRTS. HC Wainwright boosted their price objective on shares of Alpha Tau Medical from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Barclays increased their price objective on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, September 3rd. Benchmark reissued a “buy” rating on shares of Alpha Tau Medical in a research note on Thursday, July 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Friday, July 17th. Finally, Zacks Research lowered shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a report on Tuesday, September 1st.

Read Our Latest Stock Report on Alpha Tau Medical

Insiders Place Their Bets

In related news, CFO Raphi Levy sold 2,871 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $15.00, for a total value of $43,065.00. Following the completion of the sale, the chief financial officer directly owned 90,180 shares in the company, valued at approximately $1,352,700. This represents a 3.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 39.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of DRTS. Everhart Financial Group Inc. acquired a new position in shares of Alpha Tau Medical during the second quarter worth about $126,000. Renaissance Technologies LLC purchased a new stake in shares of Alpha Tau Medical in the first quarter worth about $286,000. Finally, Principal Financial Group Inc. acquired a new stake in shares of Alpha Tau Medical in the first quarter valued at about $132,000. Institutional investors and hedge funds own 2.65% of the company’s stock.

Alpha Tau Medical Stock Down 1.7%

Shares of NASDAQ:DRTS opened at $13.50 on Thursday. The stock has a 50-day simple moving average of $14.50 and a 200-day simple moving average of $11.60. The stock has a market capitalization of $1.22 billion, a P/E ratio of -12.98 and a beta of 1.22. Alpha Tau Medical has a 1 year low of $3.43 and a 1 year high of $15.79. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.79 and a current ratio of 11.09.

Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.36). Equities analysts forecast that Alpha Tau Medical will post -1.05 earnings per share for the current year.

About Alpha Tau Medical

(Get Free Report)

Alpha Tau Medical Ltd. is an Israel-based medical technology company focused on developing localized radiation treatments for solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver high-energy alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses implanted radium-224 sources that generate short-lived alpha-emitting atoms. These atoms diffuse through the treated tumor and can damage cancer cells over a localized area.

Further Reading

Analyst Recommendations for Alpha Tau Medical (NASDAQ:DRTS)

Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.